Biotech Sidesteps Consolidation
With top-tier biotechs uncertain where their follow-on products will come from, some industry executives are predicting a coming wave of consolidation. But for a variety of structural and managerial reasons, significant consolidation is unlikely. In particular, top-tier biotechs prefer in-licensing to the valuation and managerial headaches of mergers, while discovery companies question the logic of fully-integrated services.
You may also be interested in...
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Sanofi's Sarclisa for treating adults with relapsed and refractory multiple myeloma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.